X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (17042) 17042
Newsletter (125) 125
Magazine Article (48) 48
Newspaper Article (13) 13
Book / eBook (11) 11
Book Chapter (11) 11
Conference Proceeding (6) 6
Publication (2) 2
Dissertation (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12548) 12548
pyridines - therapeutic use (9352) 9352
male (7496) 7496
female (5962) 5962
animals (5844) 5844
pyridines - pharmacology (5362) 5362
middle aged (4134) 4134
adult (3501) 3501
pharmacology & pharmacy (3108) 3108
aged (3033) 3033
pyridines - administration & dosage (2774) 2774
pyridines - adverse effects (2445) 2445
oncology (2333) 2333
mice (2287) 2287
rats (2256) 2256
treatment outcome (1862) 1862
antineoplastic agents - therapeutic use (1861) 1861
cancer (1620) 1620
dose-response relationship, drug (1544) 1544
niacinamide - analogs & derivatives (1413) 1413
phenylurea compounds (1347) 1347
analysis (1214) 1214
protein kinase inhibitors - therapeutic use (1197) 1197
pyridines - pharmacokinetics (1164) 1164
neurosciences (1115) 1115
care and treatment (1057) 1057
clinical trials as topic (1039) 1039
research (1020) 1020
cell line, tumor (1010) 1010
benzenesulfonates - therapeutic use (983) 983
disease models, animal (956) 956
double-blind method (956) 956
pyridines - chemistry (938) 938
time factors (937) 937
drug therapy (933) 933
administration, oral (923) 923
pyrazoles - therapeutic use (890) 890
expression (886) 886
pyridine (882) 882
antineoplastic combined chemotherapy protocols - therapeutic use (869) 869
imidazoles - pharmacology (839) 839
rats, sprague-dawley (826) 826
pyridines (805) 805
apoptosis (794) 794
drug therapy, combination (783) 783
biochemistry & molecular biology (777) 777
chemotherapy (768) 768
aged, 80 and over (765) 765
antineoplastic agents - pharmacology (751) 751
cell biology (744) 744
medicine & public health (744) 744
sorafenib (727) 727
therapy (708) 708
health aspects (699) 699
lung neoplasms - drug therapy (698) 698
adolescent (691) 691
pharmacology/toxicology (691) 691
drug administration schedule (679) 679
activation (655) 655
hiv infections - drug therapy (654) 654
protein kinase inhibitors - pharmacology (652) 652
signal transduction - drug effects (647) 647
kinases (635) 635
pharmacokinetics (629) 629
chemistry, medicinal (627) 627
abridged index medicus (620) 620
pharmacology (618) 618
enzyme inhibitors - pharmacology (615) 615
proteins (612) 612
drug combinations (606) 606
inhibition (606) 606
mutation (579) 579
psychiatry (575) 575
cell proliferation - drug effects (569) 569
apoptosis - drug effects (567) 567
cardiac & cardiovascular systems (566) 566
drug interactions (563) 563
research article (559) 559
tumors (554) 554
signal transduction (551) 551
double-blind (550) 550
antineoplastic agents - adverse effects (549) 549
safety (548) 548
nifedipine - therapeutic use (544) 544
cells, cultured (543) 543
efficacy (543) 543
metastasis (540) 540
phosphorylation (540) 540
young adult (534) 534
anticoagulants - therapeutic use (533) 533
clinical trials (530) 530
atazanavir sulfate (529) 529
medicine (528) 528
medicine, general & internal (527) 527
dabigatran (523) 523
in-vitro (521) 521
risk factors (516) 516
multidisciplinary sciences (496) 496
hematology (492) 492
carcinoma, non-small-cell lung - drug therapy (485) 485
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (15764) 15764
Japanese (502) 502
German (429) 429
French (242) 242
Italian (234) 234
Russian (127) 127
Spanish (115) 115
Chinese (64) 64
Polish (35) 35
Czech (25) 25
Portuguese (25) 25
Dutch (20) 20
Hungarian (19) 19
Danish (14) 14
Norwegian (7) 7
Swedish (7) 7
Ukrainian (6) 6
Croatian (3) 3
Bulgarian (2) 2
Hebrew (2) 2
Romanian (2) 2
Finnish (1) 1
Serbian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European urology, ISSN 0302-2838, 2017, Volume 71, Issue 3, pp. 426 - 436
...), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. Objective To systematically review relevant literature comparing... 
Urology | Papillary | Systematic review | Sunitinib | Non-clear cell renal cell carcinoma | Everolimus | Chromophobe | carcinoma | Review | Non-clear cell renal cell | Journal Article | UROLOGY & NEPHROLOGY | PHASE-II | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bevacizumab - therapeutic use | Humans | Interleukin-2 - therapeutic use | Antineoplastic Agents - therapeutic use | Interferons - therapeutic use | Comparative Effectiveness Research | Quinolones - therapeutic use | Everolimus - therapeutic use | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoma, Renal Cell - pathology | Pyrrolidinones - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Disease-Free Survival | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Indoles - therapeutic use | Kidney Neoplasms - pathology | Erlotinib Hydrochloride - therapeutic use | Quinolines - therapeutic use | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Medical colleges | Care and treatment | Carcinoma, Renal cell | Endothelial growth factors | Analysis | Endothelium | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Clinical Medicine | Cancer and Oncology | Urology and Nephrology | Cancer och onkologi
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 09/2015, Volume 113, Issue 5, pp. 931 - 942
Summary Several new anticoagulants have entered the clinical arena or are under clinical development. These drugs include indirect (fondaparinux) and direct... 
Review Article | Rivaroxaban | Antidotes | Dabigatran | New anticoagulants | Apixaban | ANDEXANET-ALPHA | VITAMIN-K ANTAGONISTS | rivaroxaban | apixaban | ATRIAL-FIBRILLATION | antidotes | IN-VITRO | ANTIIDIOTYPIC ANTIBODIES | PROTHROMBIN COMPLEX CONCENTRATE | ORAL ANTICOAGULANTS | MOLECULAR-WEIGHT HEPARIN | dabigatran | PERIPHERAL VASCULAR DISEASE | HEALTHY-VOLUNTEERS | HEMATOLOGY | ACUTE VENOUS THROMBOEMBOLISM | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Thrombosis - complications | Humans | Antibodies, Monoclonal - therapeutic use | Heparin - therapeutic use | Hemorrhage - prevention & control | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Vitamin K - antagonists & inhibitors | Benzamides - therapeutic use | Anticoagulants - chemistry | Factor Xa - therapeutic use | Intracranial Hemorrhages - prevention & control | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Hemostatics - chemistry | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Infusions, Parenteral | Clinical Trials as Topic | Factor Xa Inhibitors - therapeutic use | Animals | Protamines - therapeutic use | Pyridones - therapeutic use | Thrombosis - drug therapy | Hemorrhage - chemically induced | Hemostatics - therapeutic use
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
Vitamin K antagonists are commonly used by clinicians to provide anticoagulation to patients who have or are at risk of having thrombotic events. In addition... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article
Cancer treatment reviews, ISSN 0305-7372, 2016, Volume 50, pp. 109 - 117
... are approved for first-line or later-line use in the treatment of patients with mRCC [1–3] . Among these agents, 1 is a monoclonal antibody targeting vascular endothelial... 
Hematology, Oncology and Palliative Medicine | Prognostic markers | Predictive markers | Sequential therapy | Overall survival | Targeted therapy | mRCC | PROGRESSION-FREE SURVIVAL | 1ST-LINE SUNITINIB | BLIND PHASE-III | OPEN-LABEL | INTERFERON-ALPHA | ONCOLOGY | 2ND-LINE TREATMENT | EXPRESSION LEVELS | CANCER-SPECIFIC SURVIVAL | CLINICAL-PRACTICE | DOSE TITRATION | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Prognosis | Humans | Gene Expression Regulation, Neoplastic | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Vascular Endothelial Growth Factor A - genetics | Sunitinib | Tumor Suppressor Proteins - genetics | Biomarkers, Tumor - metabolism | Axitinib | Everolimus - therapeutic use | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Nuclear Proteins - genetics | Pyrroles - therapeutic use | Molecular Targeted Therapy - methods | Pyridines - therapeutic use | Histone-Lysine N-Methyltransferase - genetics | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Receptors, CCR4 - genetics | Interferon-alpha - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Transcription Factors - genetics | Ubiquitin Thiolesterase - genetics | Carcinoma, Renal Cell - metabolism | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Nivolumab | Sorafenib | Indoles - therapeutic use | Kidney Neoplasms - pathology | MicroRNAs - genetics | Quinolines - therapeutic use | Mutation | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Precision Medicine - methods | Immunologic Factors - therapeutic use | Antimitotic agents | Care and treatment | Metastasis | Antineoplastic agents | Patient outcomes | Cancer
Journal Article
The American heart journal, ISSN 0002-8703, 2014, Volume 168, Issue 5, pp. 611 - 621
.... Anticoagulation uses 1 of 4 choices: bivalirudin, unfractionated heparin, enoxaparin, and fondaparinux... 
Cardiovascular | WORKING GROUP | CARDIAC & CARDIOVASCULAR SYSTEMS | ANTITHROMBOTIC THERAPY | DOUBLE-BLIND | ASSOCIATION TASK-FORCE | EUROPEAN-SOCIETY | ELEVATION MYOCARDIAL-INFARCTION | CONSENSUS DOCUMENT | PLATELET REACTIVITY | ATRIAL-FIBRILLATION | UNFRACTIONATED HEPARIN | Recombinant Proteins - therapeutic use | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Hirudins | Humans | Heparin - therapeutic use | Enoxaparin - therapeutic use | Tyrosine - analogs & derivatives | Receptors, Thrombin - antagonists & inhibitors | Warfarin - therapeutic use | Tyrosine - therapeutic use | Adenosine - therapeutic use | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Purinergic P2Y Receptor Antagonists - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Anticoagulants - therapeutic use | Piperazines - therapeutic use | Adenosine Monophosphate - therapeutic use | Lactones - therapeutic use | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Adenosine Monophosphate - analogs & derivatives | Peptide Fragments - therapeutic use | Peptides - therapeutic use | Aspirin | Glycosaminoglycans | Atrial fibrillation | Mortality | Thrombin | Anticoagulants (Medicine) | Health aspects | Drug approval | Coronary heart disease | Heart attacks | Acute coronary syndromes | Drug therapy | Clinical outcomes
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 03/2018, Volume 2018, Issue 3, p. CD011481
Journal Article
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 44, pp. 61 - 73
Journal Article
European Urology, ISSN 0302-2838, 2011, Volume 61, Issue 5, pp. 950 - 960
...) progression has led to the recognition of multiple molecular targets and advances in the therapeutic landscape... 
Urology | Molecular targets | Chemotherapy | Immunotherapy | Androgen pathway inhibitors | Biologic agents | Androgen receptor | Prostate cancer | Skeletal-related events | ADVANCED SOLID TUMORS | DOCETAXEL | PATHWAY ACTIVATION | MITOXANTRONE PLUS PREDNISONE | INHIBITION | RANDOMIZED PHASE-II | CLINICAL-TRIALS | UROLOGY & NEPHROLOGY | END-POINTS | HIGH-DOSE CALCITRIOL | Receptors, Vascular Endothelial Growth Factor | Anilides - therapeutic use | Phenylthiohydantoin - therapeutic use | Humans | Ipilimumab | Recombinant Fusion Proteins - therapeutic use | Bone Neoplasms - secondary | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Thiazoles - therapeutic use | Abiraterone Acetate | Quinolones | Antibodies, Monoclonal, Humanized | Taxoids - therapeutic use | Cancer Vaccines - therapeutic use | Clinical Trials, Phase III as Topic | Bone Neoplasms - drug therapy | Clusterin - therapeutic use | Prostatic Neoplasms - drug therapy | Carcinoma - secondary | Pyridines - therapeutic use | Carcinoma - drug therapy | Dasatinib | Prostatic Neoplasms - pathology | Prostatic Neoplasms - surgery | Carcinoma - surgery | Treatment Outcome | Vaccines, Synthetic - therapeutic use | Tissue Extracts - therapeutic use | Denosumab | Radium - therapeutic use | Phenylthiohydantoin - analogs & derivatives | Orchiectomy | Pyrimidines - therapeutic use | Androstadienes - therapeutic use | Quinolines - therapeutic use | Medical colleges | Hospitals | Development and progression | Metastasis | Tubulins | Cancer | Landscape | Conferences | Immunoregulation | Clinical trials | Data processing | Oncology | Src protein | Clusterin | Metastases | Angiogenesis | Signal transduction | Androgens | Antagonism | Databases | Reviews | Tubulin | Acetic acid
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 5, pp. 482 - 487
Purpose Complete remission (CR) is uncommon during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs), but it may... 
TARGETED THERAPY | SURVIVAL | INTERFERON-ALPHA | METASTASIS | EFFICACY | ONCOLOGY | DOSE RECOMBINANT INTERLEUKIN-2 | SUNITINIB | RESISTANCE | UPDATE | PROGRESSION | Niacinamide - analogs & derivatives | Humans | Middle Aged | Carcinoma, Renal